Ajinomoto (2802) Investor update summary
Event summary combining transcript, slides, and related documents.
Investor update summary
30 Jun, 2026Market outlook and growth drivers
Logic IC market is forecast to grow by 37% in 2026 and 27% in 2027, driven by AI-related demand.
Semiconductor evolution from learning to inference is increasing demand for high-performance substrates.
Package substrates are becoming larger and more layered, increasing ABF™ usage per substrate.
Robust performance in FY2026 with no current supply chain concerns; expansion plans target 2030 and beyond.
ABF™ maintains over 95% market share, leveraging early-stage customer collaboration.
Business model and product innovation
ABF™ is custom-developed for each customer, optimizing both price and performance through collaborative development.
Product lineup is shifting toward higher value-added products, raising profit margins from 30% in FY2018 to over 50% in FY2025.
Ongoing development of peripheral materials and next-generation packaging technologies, including co-packaged optics.
Expansion into adhesive, molding, and magnetic materials for advanced semiconductor applications.
Focus on evolving ABF™ for future technologies such as optical waveguides and heterogeneous integration.
Production and supply chain strategy
New Gunma Plant, operational since 2025, features state-of-the-art automation and IoT systems for efficiency.
Investment of ¥25 billion planned between 2023 and 2030 to expand production capacity, including a new Gifu site for post-2030 demand.
Production structure includes in-house varnish manufacturing and outsourced film application and storage.
Global network supports customer growth with sites in Japan, China, Taiwan, and the US.
High-speed development system anticipates customer needs and integrates feedback across the value chain.
Latest events from Ajinomoto
- Record sales and profit growth led to upward forecasts and increased shareholder returns.2802
Q2 20251 Jul 2026 - Record sales and profit highs, with raised full-year profit outlook and strong segment momentum.2802
Q3 202630 Jun 2026 - Global leader in amino acid science targets growth, health impact, and major sustainability gains.2802
Investor presentation30 Jun 2026 - Record profit and sales growth achieved, with further gains targeted amid managed global risks.2802
Q4 202613 May 2026 - Integrated sustainability and agri-food innovation drive growth and aim to double key solution sales by 2030.2802
Investor Day 20266 May 2026 - Governance, compensation, and management reforms drive long-term growth and value creation.2802
Investor update9 Apr 2026 - Record Q1 sales and profit, but net profit fell 12% due to a temporary tax impact.2802
Q1 20252 Feb 2026 - Record sales and profit growth led by overseas, healthcare, and currency gains amid cost pressures.2802
Q3 20259 Jan 2026 - Profit attributable to owners rose 2% as H1 results were flat, with strong H2 recovery expected.2802
Q2 202610 Dec 2025